N-able Q3 revenue $93.5M (+6% YoY), beats outlook; raises FY2022 adjusted EBITDA margin guidance to 30%

N-able, Inc.

2022-Q3 EPS reported $0.05 revenue$276,014,000

Total revenue $93.5M, up 6% YoY (13% constant currency); subscription revenue $91.2M (+6% YoY, +13% constant currency).
GAAP net income $0.3M ($0.00 EPS); non-GAAP net income $12.3M ($0.07 EPS); adjusted EBITDA $28.8M (30.9% margin).
Raised FY2022 adjusted EBITDA margin outlook to 30%, reaffirmed total revenue growth of ~7% YoY (12-13% constant currency).
TTM dollar-based net retention rate 104% including ~4 points of negative FX impact.
Cash $87.7M, total debt $337.5M at quarter end.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

N-able, Inc. reported third quarter ended September 30, 2022 results: revenue $93.5 million, net income $0.3 million, or $0.00 per diluted share, EPS $0.00 per diluted share. Guidance raised.

Period: third quarter ended September 30, 2022
Revenue: $93.5 million
Net income: $0.3 million, or $0.00 per diluted share
EPS: $0.00 per diluted share
Guidance: raised
Result: reported results

Exact text from the filing

prioritize our growth-oriented investments while maintaining cost discipline across other aspects of the business." Third quarter 2022 financial highlights: • Total revenue of $93.5 million, representing approximately 6% year-over-year growth, or approximately 13% year-over-year growth on a constant currency basis. • Subscription revenue of $91.2 million,

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

N-able, Inc. filing history →

Source: SEC EDGAR

accession 0001834488-22-000144

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.